Patents by Inventor Paul D. Rubin

Paul D. Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220054528
    Abstract: The present disclosure provides methods for treating Adult T-cell Leukemia/Lymphoma (ATLL) in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. In some embodiments, the subject may have received one or more therapies for treating ATLL prior to receiving the oligonucleotide inhibitor of miR-155. Administration of an oligonucleotide inhibitor of miR-155 according to the methods of the present disclosure can decrease the tumor cell count or can maintain the tumor cell count at or below the tumor cell count at the beginning of administration of the oligonucleotide inhibitor of miR-155. Accordingly, the methods provided in this disclosure can be used as maintenance therapies for treating ATLL subjects.
    Type: Application
    Filed: May 15, 2019
    Publication date: February 24, 2022
    Inventors: Diana M. ESCOLAR, Linda Anne PESTANO, Paul D. RUBIN
  • Publication number: 20200376019
    Abstract: Provided herein are double-stranded, chemically-modified oligonucleotide mimetics of miR-29 for use in treating ocular diseases or disorders associated with ocular fibrosis, and ocular fibrotic conditions.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 3, 2020
    Inventors: Corrie Lynn GALLANT-BEHM, Aimee JACKSON, Stephanie PROPP, Paul D. RUBIN
  • Patent number: 8404715
    Abstract: Methods and pharmaceutical compositions employing a terfenadine metabolite and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof. Also included are methods and compositions employing a terfenadine metabolite, a leukotriene inhibitor, and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: March 26, 2013
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventor: Paul D. Rubin
  • Publication number: 20120149730
    Abstract: Methods and pharmaceutical compositions employing a terfenadine metabolite and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof. Also included are methods and compositions employing a terfenadine metabolite, a leukotriene inhibitor, and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof.
    Type: Application
    Filed: February 16, 2012
    Publication date: June 14, 2012
    Inventor: Paul D. RUBIN
  • Patent number: 7064138
    Abstract: Methods for the prophylaxis, treatment, or management of irritable bowel syndrome using (?) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer are disclosed.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: June 20, 2006
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Patent number: 7030142
    Abstract: The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: April 18, 2006
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • Patent number: 6946464
    Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: September 20, 2005
    Assignee: Sepracor Inc.
    Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
  • Patent number: 6835740
    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia, nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: December 28, 2004
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Publication number: 20040224989
    Abstract: Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also-useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: June 8, 2004
    Publication date: November 11, 2004
    Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
  • Publication number: 20040225020
    Abstract: Methods and compositions are disclosed utilizing the optically pure (−)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.
    Type: Application
    Filed: May 19, 2004
    Publication date: November 11, 2004
    Applicant: Sepracor Inc.
    Inventors: John R. McCullough, Paul D. Rubin
  • Patent number: 6790849
    Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: September 14, 2004
    Assignee: Sepracor Inc.
    Inventor: Paul D. Rubin
  • Publication number: 20040171647
    Abstract: Methods and compositions are disclosed utilizing optically pure S(−)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(−) isomer is also useful for the treatment of gastroesophageal reflux. S(−)rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: March 8, 2004
    Publication date: September 2, 2004
    Applicant: Sepracor Inc.
    Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
  • Publication number: 20040058973
    Abstract: Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer
    Type: Application
    Filed: September 22, 2003
    Publication date: March 25, 2004
    Applicant: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Publication number: 20040019111
    Abstract: Methods of treating neuropathic pain, tinnitus, and related disorders are disclosed. These methods comprise the administration of optically pure R(−)-ketoprofen. Also disclosed are pharmaceutical compositions useful in the treatment of neuropathic pain and tinnitus which comprise optically pure R(−)-ketoprofen.
    Type: Application
    Filed: July 17, 2003
    Publication date: January 29, 2004
    Applicant: Sepracor, Inc.
    Inventors: Thomas P. Jerussi, Paul D. Rubin
  • Patent number: 6649183
    Abstract: Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: November 18, 2003
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Patent number: 6620851
    Abstract: Methods of treating neuropathic pain, tinnitus, and related disorders are disclosed. These methods comprise the administration of optically pure R(−)-ketoprofen. Also disclosed are pharmaceutical compositions useful in the treatment of neuropathic pain and tinnitus which comprise optically pure R(−)-ketoprofen.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: September 16, 2003
    Assignee: Sepracor, Inc.
    Inventors: Thomas P. Jerussi, Paul D. Rubin
  • Publication number: 20030166657
    Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.
    Type: Application
    Filed: January 13, 2003
    Publication date: September 4, 2003
    Applicant: Sepracor, Inc.
    Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
  • Publication number: 20030158229
    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.
    Type: Application
    Filed: February 26, 2003
    Publication date: August 21, 2003
    Applicant: SEPRACOR INC.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Patent number: 6586437
    Abstract: Treatment of psychoses with (S)-hydroxynefazodone is disclosed.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: July 1, 2003
    Assignee: Sepracor Inc.
    Inventors: Mark G. Currie, Thomas P. Jerussi, Paul D. Rubin
  • Publication number: 20030119841
    Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.
    Type: Application
    Filed: September 30, 2002
    Publication date: June 26, 2003
    Applicant: Sepracor, Inc.
    Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville